Skip to main content
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1990 Aug;137(2):331–339.

Immunotherapy of collagen-induced arthritis by a T-cell antiproliferative molecule.

D J Spannaus-Martin 1, R Holmdahl 1, T F Kresina 1
PMCID: PMC1877607  PMID: 2201199

Abstract

The present study describes a novel experimental immunotherapeutic methodology for the reduction of inflammatory synovitis that is noted in an animal model of rheumatoid arthritis. The reduction in inflammation is noted in the animals administered a contra-interleukin-2 (IL-2) cytokine secreted by a cloned T-cell line. The mechanism of reduction of inflammation by this cytokine is through the inhibition of activation and differentiation of T lymphocytes. The cytokine inhibits the in vitro mitogen activation of T-cell lymphocytes as well as antigen-specific activation of a collagen type II specific T-cell line. In addition, decreased levels of messenger RNA coding for interleukin-2 are noted in T lymphocytes and IL-2 activation of the collagen type II specific cell line is inhibited by the contra-IL-2 cytokine. This initial description of a reduction in inflammation by a contra-IL-2 lymphokine suggests that immunoregulatory biologic molecules that are antagonists to IL-2 may be useful for the experimental immunotherapy of cartilage connective tissue pathology.

Full text

PDF
331

Images in this article

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benacerraf B., Germain R. N. A single major pathway of T-lymphocyte interactions in antigen-specific immune suppression. Scand J Immunol. 1981;13(1):1–10. doi: 10.1111/j.1365-3083.1981.tb00104.x. [DOI] [PubMed] [Google Scholar]
  2. Buchan G., Barrett K., Fujita T., Taniguchi T., Maini R., Feldmann M. Detection of activated T cell products in the rheumatoid joint using cDNA probes to Interleukin-2 (IL-2) IL-2 receptor and IFN-gamma. Clin Exp Immunol. 1988 Feb;71(2):295–301. [PMC free article] [PubMed] [Google Scholar]
  3. Dallman M., Fathman C. G. Type II collagen-reactive T cell clones from mice with collagen-induced arthritis. J Immunol. 1985 Aug;135(2):1113–1118. [PubMed] [Google Scholar]
  4. Decker J. L., Malone D. G., Haraoui B., Wahl S. M., Schrieber L., Klippel J. H., Steinberg A. D., Wilder R. L. NIH conference. Rheumatoid arthritis: evolving concepts of pathogenesis and treatment. Ann Intern Med. 1984 Dec;101(6):810–824. doi: 10.7326/0003-4819-101-6-810. [DOI] [PubMed] [Google Scholar]
  5. Dorf M. E., Benacerraf B. Suppressor cells and immunoregulation. Annu Rev Immunol. 1984;2:127–157. doi: 10.1146/annurev.iy.02.040184.001015. [DOI] [PubMed] [Google Scholar]
  6. Fresno M., McVay-Boudreau L., Nabel G., Cantor H. Antigen-specific T lymphocyte clones. II. Purification and biological characterization of an antigen-specific suppressive protein synthesized by cloned T cells. J Exp Med. 1981 May 1;153(5):1260–1274. doi: 10.1084/jem.153.5.1260. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gershon R. K., Kondo K. Cell interactions in the induction of tolerance: the role of thymic lymphocytes. Immunology. 1970 May;18(5):723–737. [PMC free article] [PubMed] [Google Scholar]
  8. Gillis S. Interleukin 2: biology and biochemistry. J Clin Immunol. 1983 Jan;3(1):1–13. doi: 10.1007/BF00919133. [DOI] [PubMed] [Google Scholar]
  9. Goldsby R. A., Osborne B. A., Simpson E., Herzenberg L. A. Hybrid cell lines with T-cell characteristics. Nature. 1977 Jun 23;267(5613):707–708. doi: 10.1038/267707a0. [DOI] [PubMed] [Google Scholar]
  10. Greene W. C., Leonard W. J., Depper J. M. Growth of human T lymphocytes: an analysis of interleukin 2 and its cellular receptor. Prog Hematol. 1986;14:283–301. [PubMed] [Google Scholar]
  11. Hagiwara H., Yokota T., Luh J., Lee F., Arai K., Arai N., Zlotnik A. The AKR thymoma BW5147 is able to produce lymphokines when stimulated with calcium ionophore and phorbol ester. J Immunol. 1988 Mar 1;140(5):1561–1565. [PubMed] [Google Scholar]
  12. Helfgott S. M., Dynesius-Trentham R., Brahn E., Trentham D. E. An arthritogenic lymphokine in the rat. J Exp Med. 1985 Nov 1;162(5):1531–1545. doi: 10.1084/jem.162.5.1531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Holmdahl R., Jonsson R., Larsson P., Klareskog L. Early appearance of activated CD4+ T lymphocytes and class II antigen-expressing cells in joints of DBA/1 mice immunized with type II collagen. Lab Invest. 1988 Jan;58(1):53–60. [PubMed] [Google Scholar]
  14. Holmdahl R., Klareskog L., Rubin K., Larsson E., Wigzell H. T lymphocytes in collagen II-induced arthritis in mice. Characterization of arthritogenic collagen II-specific T-cell lines and clones. Scand J Immunol. 1985 Sep;22(3):295–306. doi: 10.1111/j.1365-3083.1985.tb01884.x. [DOI] [PubMed] [Google Scholar]
  15. Holmdahl R., Rubin K., Klareskog L., Dencker L., Gustafson G., Larsson E. Appearance of different lymphoid cells in synovial tissue and in peripheral blood during the course of collagen II-induced arthritis in rats. Scand J Immunol. 1985 Mar;21(3):197–204. doi: 10.1111/j.1365-3083.1985.tb01421.x. [DOI] [PubMed] [Google Scholar]
  16. Hom J. T., Stuart J. M., Chiller J. M. Murine T cells reactive to type II collagen. I. Isolation of lines and clones and characterization of their antigen-induced proliferative responses. J Immunol. 1986 Feb 1;136(3):769–775. [PubMed] [Google Scholar]
  17. Hom J. T., Stuart J. M., Tovey J., Chiller J. M. Murine T cells reactive to type II collagen. II. Functional characterization. J Immunol. 1986 Feb 1;136(3):776–782. [PubMed] [Google Scholar]
  18. Honda M., Chan C., Shevach E. M. Characterization and partial purification of a specific interleukin 2 inhibitor. J Immunol. 1985 Sep;135(3):1834–1839. [PubMed] [Google Scholar]
  19. Janossy G., Panayi G., Duke O., Bofill M., Poulter L. W., Goldstein G. Rheumatoid arthritis: a disease of T-lymphocyte/macrophage immunoregulation. Lancet. 1981 Oct 17;2(8251):839–842. doi: 10.1016/s0140-6736(81)91107-7. [DOI] [PubMed] [Google Scholar]
  20. Kapp J. A., Araneo B. A., Clevinger B. L. Suppression of antibody and T cell proliferative responses to L-glutamic acid60-L-alanine30-L-tyrosine10 by a specific monoclonal T cell factor. J Exp Med. 1980 Jul 1;152(1):235–240. doi: 10.1084/jem.152.1.235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Kasaian M. T., Biron C. A. The activation of IL-2 transcription in L3T4+ and Lyt-2+ lymphocytes during virus infection in vivo. J Immunol. 1989 Feb 15;142(4):1287–1292. [PubMed] [Google Scholar]
  22. Kashiwado T., Miossec P., Oppenheimer-Marks N., Ziff M. Inhibitor of interleukin-2 synthesis and response in rheumatoid synovial fluid. Arthritis Rheum. 1987 Dec;30(12):1339–1347. doi: 10.1002/art.1780301204. [DOI] [PubMed] [Google Scholar]
  23. Klareskog L., Holmdahl R., Larsson E., Wigzell H. Role of T lymphocytes in collagen II induced arthritis in rats. Clin Exp Immunol. 1983 Jan;51(1):117–125. [PMC free article] [PubMed] [Google Scholar]
  24. Kobayashi K., Kasama T., Fukushima T., Kasahara K., Tabata M., Sekine F., Negishi M., Ide H., Takahashi T. Deficiency of interleukin 2 inhibitor activity in serum from autoimmune-prone mice. Immunol Invest. 1987 Mar;16(1):45–55. doi: 10.3109/08820138709055711. [DOI] [PubMed] [Google Scholar]
  25. Kotzin B. L., Strober S., Engleman E. G., Calin A., Hoppe R. T., Kansas G. S., Terrell C. P., Kaplan H. S. Treatment of intractable rheumatoid arthritis with total lymphoid irradiation. N Engl J Med. 1981 Oct 22;305(17):969–976. doi: 10.1056/NEJM198110223051702. [DOI] [PubMed] [Google Scholar]
  26. Kresina T. F. A contra-IL-2 cytokine derived from mice suppressed for collagen-induced arthritis. Cell Immunol. 1990 Jan;125(1):171–182. doi: 10.1016/0008-8749(90)90072-y. [DOI] [PubMed] [Google Scholar]
  27. Kresina T. F. Antigen specific down regulation of murine collagen induced arthritis: T suppressor cell circuits in arthritis immunotherapy. Int Rev Immunol. 1988 Sep;4(1):91–106. doi: 10.3109/08830188809044773. [DOI] [PubMed] [Google Scholar]
  28. Kresina T. F. Down-regulation of murine collagen-induced arthritis by a T cell hybridoma. Exp Cell Biol. 1988;56(1-2):86–102. doi: 10.1159/000163466. [DOI] [PubMed] [Google Scholar]
  29. Kresina T. F. Immunotherapy of experimental arthritis. Analysis of the articular cartilage of mice suppressed for collagen-induced arthritis by a T-cell hybridoma. Am J Pathol. 1987 Nov;129(2):257–266. [PMC free article] [PubMed] [Google Scholar]
  30. Lawrence J. B., Singer R. H. Quantitative analysis of in situ hybridization methods for the detection of actin gene expression. Nucleic Acids Res. 1985 Mar 11;13(5):1777–1799. doi: 10.1093/nar/13.5.1777. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Lelchuk R., Playfair J. H. Serum IL-2 inhibitor in mice. I. Increase during infection. Immunology. 1985 Sep;56(1):113–118. [PMC free article] [PubMed] [Google Scholar]
  32. Lider O., Reshef T., Beraud E., Ben-Nun A., Cohen I. R. Anti-idiotypic network induced by T cell vaccination against experimental autoimmune encephalomyelitis. Science. 1988 Jan 8;239(4836):181–183. doi: 10.1126/science.2447648. [DOI] [PubMed] [Google Scholar]
  33. Lindblad S., Klareskog L., Hedfors E., Forsum U., Sundström C. Phenotypic characterization of synovial tissue cells in situ in different types of synovitis. Arthritis Rheum. 1983 Nov;26(11):1321–1332. doi: 10.1002/art.1780261104. [DOI] [PubMed] [Google Scholar]
  34. Londei M., Savill C. M., Verhoef A., Brennan F., Leech Z. A., Duance V., Maini R. N., Feldmann M. Persistence of collagen type II-specific T-cell clones in the synovial membrane of a patient with rheumatoid arthritis. Proc Natl Acad Sci U S A. 1989 Jan;86(2):636–640. doi: 10.1073/pnas.86.2.636. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Maki T., Satomi S., Gotoh M., Monaco A. P. Contra-IL 2 activity of a lymphokine produced by a hybrid cell line of ALS-induced suppressor T cells. Transplant Proc. 1987 Feb;19(1 Pt 1):531–533. [PubMed] [Google Scholar]
  36. Maki T., Satomi S., Gotoh M., Monaco A. P. Contra-IL 2; a suppressor lymphokine that inhibits IL 2 activity. J Immunol. 1986 May 1;136(9):3298–3303. [PubMed] [Google Scholar]
  37. Male D., Lelchuk R., Curry S., Pryce G., Playfair J. H. Serum IL-2 inhibitor in mice. II. Molecular characteristics. Immunology. 1985 Sep;56(1):119–125. [PMC free article] [PubMed] [Google Scholar]
  38. Malkovsky M., Asherson G. L., Stockinger B., Watkins M. C. Nonspecific inhibitor released by T acceptor cells reduces the production of interleukin-2. Nature. 1982 Dec 16;300(5893):652–655. doi: 10.1038/300652a0. [DOI] [PubMed] [Google Scholar]
  39. Malkovský M., Asherson G. L., Chandler P., Colizzi V., Watkins M. C., Zembala M. Nonspecific inhibitor of DNA synthesis elaborated by T acceptor cells. I. Specific hapten- and I-J-driven liberation of an inhibitor of cell proliferation by Lyt-1-2+ cyclophosphamide-sensitive T acceptor cells armed with a product of Lyt-1+2+-specific suppressor cells. J Immunol. 1983 Feb;130(2):785–790. [PubMed] [Google Scholar]
  40. McKenna R. M., Ofosu-Appiah W., Warrington R. J., Wilkins J. A. Interleukin 2 production and responsiveness in active and inactive rheumatoid arthritis. J Rheumatol. 1986 Feb;13(1):28–32. [PubMed] [Google Scholar]
  41. Paulus H. E., Machleder H. I., Levine S., Yu D. T., MacDonald N. S. Lymphocyte involvement in rheumatoid arthritis. Studies during thoracic duct drainage. Arthritis Rheum. 1977 Jul-Aug;20(6):1249–1262. doi: 10.1002/art.1780200614. [DOI] [PubMed] [Google Scholar]
  42. Pfizenmaier K., Scheurich P., Däubener W., Krönke M., Röllinghoff M., Wagner H. Quantitative representation of all T cells committed to develop into cytotoxic effector cells and/or interleukin 2 activity-producing helper cells within murine T lymphocyte subsets. Eur J Immunol. 1984 Jan;14(1):33–39. doi: 10.1002/eji.1830140107. [DOI] [PubMed] [Google Scholar]
  43. Poulter L. W., Duke O., Panayi G. S., Hobbs S., Raftery M. J., Janossy G. Activated T lymphocytes of the synovial membrane in rheumatoid arthritis and other arthropathies. Scand J Immunol. 1985 Dec;22(6):683–690. doi: 10.1111/j.1365-3083.1985.tb01931.x. [DOI] [PubMed] [Google Scholar]
  44. Pruett S. B., Lackey A. Apparent interleukin 2 (IL-2) inhibitory activity of human serum is due to rapid killing of IL-2-dependent mouse cells. Clin Exp Immunol. 1987 Sep;69(3):624–631. [PMC free article] [PubMed] [Google Scholar]
  45. Rich R. R., Pierce C. W. Biological expressions of lymphocyte activation. 3. Suppression of plaque-forming cell responses in vitro by supernatant fluids from concanavalin A-activated spleen cell cultures. J Immunol. 1974 Apr;112(4):1360–1368. [PubMed] [Google Scholar]
  46. Stamenkovic I., Stegagno M., Wright K. A., Krane S. M., Amento E. P., Colvin R. B., Duquesnoy R. J., Kurnick J. T. Clonal dominance among T-lymphocyte infiltrates in arthritis. Proc Natl Acad Sci U S A. 1988 Feb;85(4):1179–1183. doi: 10.1073/pnas.85.4.1179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Stuart J. M., Townes A. S., Kang A. H. Nature and specificity of the immune response to collagen in type II collagen-induced arthritis in mice. J Clin Invest. 1982 Mar;69(3):673–683. doi: 10.1172/JCI110495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Tan P., Shore A., Leary P., Keystone E. C. Interleukin abnormalities in recently active rheumatoid arthritis. J Rheumatol. 1984 Oct;11(5):593–596. [PubMed] [Google Scholar]
  49. Taniguchi M., Tokuhisa T., Kanno M., Yaoita Y., Shimizu A., Honjo T. Reconstitution of antigen-specific suppressor activity with translation products of mRNA. Nature. 1982 Jul 8;298(5870):172–174. doi: 10.1038/298172a0. [DOI] [PubMed] [Google Scholar]
  50. Trentham D. E., Belli J. A., Anderson R. J., Buckley J. A., Goetzl E. J., David J. R., Austen K. F. Clinical and immunologic effects of fractionated total lymphoid irradiation in refractory rheumatoid arthritis. N Engl J Med. 1981 Oct 22;305(17):976–982. doi: 10.1056/NEJM198110223051703. [DOI] [PubMed] [Google Scholar]
  51. Trentham D. E., Townes A. S., Kang A. H., David J. R. Humoral and cellular sensitivity to collagen in type II collagen-induced arthritis in rats. J Clin Invest. 1978 Jan;61(1):89–96. doi: 10.1172/JCI108929. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Wahl S. M., Wilder R. L., Katona I. M., Wahl L. M., Allen J. B., Scher I., Decker J. L. Leukapheresis in rheumatoid arthritis. Association of clinical improvement with reversal of anergy. Arthritis Rheum. 1983 Sep;26(9):1076–1084. doi: 10.1002/art.1780260904. [DOI] [PubMed] [Google Scholar]
  53. Whitaker R. B., Nepom J. T., Sy M. S., Takaoki M., Gramm C. F., Fox I., Germain R. N., Nelles M. J., Greene M. I., Benacerraf B. Suppressor factor from a T cell hybrid inhibits delayed-type hypersensitivity responses to azobenzenearsonate. Proc Natl Acad Sci U S A. 1981 Oct;78(10):6441–6445. doi: 10.1073/pnas.78.10.6441. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Wolf R. E., Hall V. C. Interleukin-2 production and effect of thymosin fraction 5 on interleukin-2 production in rheumatoid arthritis. J Rheumatol. 1987 Oct;14(5):898–901. [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES